5-methoxy-1-indanone oxime | 90921-94-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 5-methoxy-1-indanone oxime
• 英文别名: 5-Methoxy-1-indanon-oxim；5-Methoxy-indanon-(1)-oxim；5-methoxy-indan-1-one oxime；5-Methoxy-indan-1-on-oxim；5-methoxy-2,3-dihydroinden-1-one oxime；5-Methoxyindan-1-one oxime；N-(5-methoxy-2,3-dihydroinden-1-ylidene)hydroxylamine
• CAS: 90921-94-1
• 化学式: C₁₀H₁₁NO₂
• 分子量: 177.203
• InChiKey: ROZVRQXOAGSIOW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  41.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-methoxy-1-indanone oxime 生成 N-(5-Methoxy-indan-1-yl)-guanidine
  参考文献：
  名称：

  Conformational analogs of antihypertensive agents related to guanethidine

  摘要：

  In an effort to clarify the conformational requirements, if any, of agents producing adrenergic neuronal blockade through mechanisms similar to guanethidine, the synthesis and pharmacological evaluation of 15 analogues of cinnamylguanidine are described. These analogues represent derivatives in which the distance between the center of the ring system and the guanidinium nitrogen atom varies from 3.9 to 6.2 A. While conformational relationships could not be defined in this study, three analogues (3, 4, and 5) were apparently more potent than guanethidine in the in vitro assay employed.

  DOI：

  10.1021/jm00216a007
• 作为产物：
  描述：

  5-甲氧基-1-茚酮 在 盐酸羟胺 、 sodium acetate 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 1.5h， 生成 5-methoxy-1-indanone oxime
  参考文献：
  名称：

  Comestible compositions comprising high potency savory flavorants, and processes for producing them

  摘要：

  本发明涉及使用某些高效的鲜味（"鲜味"）味道调节剂，作为鲜味调味剂和/或谷氨酸钠的增强剂，用于制备食品、饮料和其他可食用组合物，并涉及用于制备用于制备可食用食品和饮料的食品香精组合物的过程。

  公开号：

  US08148536B2

文献信息

• Multicyclic bis-amide MMP inhibitors
  申请人：Powers Timothy

  公开号：US20060173183A1

  公开（公告）日：2006-08-03

  The present invention relates generally to bis-amide group containing pharmaceutical agents, and in particular, to multicyclic bis-amide MMP-13 inhibitor compounds. More particularly, the present invention provides a new class of MMP-13 inhibiting compounds, containing a pyrimidinyl bis-amide group in combination with a heterocyclic moiety, that exhibit an increased potency and solubility in relation to currently known bis-amide group containing MMP-13 inhibitors.

  本发明总体涉及含有双酰胺基团的药物制剂，特别是多环双酰胺MMP-13抑制剂化合物。更具体地，本发明提供了一类新型的MMP-13抑制化合物，它们含有与杂环部分结合的嘧啶基双酰胺基团，与目前已知含双酰胺基团的MMP-13抑制剂相比，显示出增加的活性和溶解度。
• I2-Catalyzed Oxidative Coupling of Ketone Oximes and Dialkyl/Diarylphosphine Oxides
  作者：Qingle Zeng、Nutao Li、Yiding Wang、Hongqin Yang、Ze He

  DOI：10.1055/s-0040-1707306

  日期：2021.1

  protocol for the oxidative coupling of ketone oximes with dialkyl/diarylphosphine oxides to synthesize O-(dialkylphosphinyl)ketone oximes has been developed. Hydrogen peroxide is used as a green oxidizing agent, and molecular iodine is used as a nonmetal catalyst. The reaction has a high atom economy, with water as the only byproduct. O-(Dialkylphosphinyl)ketone oximes with 26 examples have been obtained

  已经开发了一种用于将酮肟与二烷基/二芳基氧化膦氧化偶联以合成 O-(二烷基膦基) 酮肟的新协议。过氧化氢用作绿色氧化剂，分子碘用作非金属催化剂。该反应具有高原子经济性，水是唯一的副产品。O-(二烷基膦基)酮肟以高收率获得了26个实例。此外，产物可以转化为其他分子，即通过还原。
• O-(二烷基次膦酰基)酮肟的合成方法
  申请人：成都理工大学

  公开号：CN110669070B

  公开（公告）日：2021-08-27

  O‑(二烷基次膦酰基)酮肟在药物和有机合成有着重要用途。本申请开发出一种新的酮肟与二烷基膦氧化物的氧化偶联方法。过氧化氢用作绿色氧化剂，分子碘用作非金属催化剂，该反应具有较高的原子经济性，且副产物仅是水。另外，该反应避免了贝克曼重排反应的发生，并且以高收率获得了26种O‑(二烷基次膦酰基)酮肟目标产物。
• [EN] (FUSED RING ARYLAMINO AND HETEROCYCLYLAMINO) PYRIMIDYNYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE IN TREATING PROLIFERATIVE DISEASES<br/>[FR] (ARYLAMINO ET HÉTÉROCYCLYLAMINO À CYCLE CONDENSÉ)PYRIMIDINYL- ET 1,3,5-TRIAZINYLBENZIMIDAZOLES, COMPOSITIONS PHARMACEUTIQUES DE CEUX-CI ET LEUR UTILISATION DANS LE TRAITEMENT DE MALADIES PROLIFÉRATIVES
  申请人：PATHWAY THERAPEUTICS INC

  公开号：WO2012135166A1

  公开（公告）日：2012-10-04

  Provided herein are (fused ring arylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, e.g., a compound of Formula (I), and their pharmaceutical compositions, preparation, and use as agents or drugs for treating proliferative diseases.

  本文提供了（融合环芳基氨基和杂环基氨基）嘧啶基和1,3,5-三嗪基苯并咪唑化合物，例如公式（I）中的化合物，以及它们的制备方法、药物组成物和作为治疗增生性疾病的药物或制剂的用途。
• Isoquinolyl substituted hydroxylamine derivatives
  申请人：Ciba-Geigy Corporation

  公开号：US05260316A1

  公开（公告）日：1993-11-09

  The compounds of the formula ##STR1## wherein R represents hydrogen, lower alkyl, aryl, biaryl, C.sub.3 -C.sub.7 -cycloalkyl, aryl-lower alkyl, aryl-lower alkenyl, aryl-lower alkynyl, aryloxy-lower alkyl, arylthio-lower alkyl; C.sub.3 -C.sub.7 -cycloalkyl-lower alkyl, biaryl-lower alkyl, aryl-C.sub.3 -C.sub.7 -cycloalkyl, aryl-C.sub.3 -C.sub.7 -cycloalkyl-lower alkyl or aryloxy-aryl-lower alkyl; and aryl represents carbocyclic or heterocyclic aryl; Z represents C.sub.1 -C.sub.3 -alkylene or vinylene, each unsubstituted or substituted by lower alkyl; Y represents SO.sub.2 or CO; A represents O, S, or a direct bond; B represents lower alkylene; or B represents lower alkenylene provided that A represents a direct bond; X represents oxygen or sulfur; R.sub.1 represents hydrogen, acyl, lower alkoxycarbonyl, aminocarbonyl, mono or di-lower alkylaminocarbonyl, lower alkenylaminocarbonyl, lower alkynylaminocarbonyl, carbocyclic or heterocyclic aryl-lower alkylaminocarbonyl, carbocyclic or heterocyclic arylaminocarbonyl, C.sub.3 -C.sub.7 -cycloalkylaminocarbonyl or C.sub.3 -C.sub.7 -cycloalkyl-lower alkylaminocarbonyl; R.sub.2 represents lower alkyl, lower alkoxycarbonyl-lower alkyl, C.sub.3 -C.sub.7 -cycloalkyl, carbocyclic or heterocyclic aryl, carbocyclic or heterocyclic aryl-lower alkyl, C.sub.3 -C.sub.7 -cycloalkyl-lower alkyl, amino, mono- or di-lower alkylamino, lower alkenylamino, lower alkynylamino, carbocyclic or heterocyclic aryl-lower alkylamino, carbocyclic or heterocyclic arylamino, C.sub.3 -C.sub.7 -cycloalkylamino, C.sub.3 -C.sub.7 -cycloalkyl-lower alkylamino or lower alkoxycarbonyl-lower alkylamino; R.sub.3 and R.sub.4 independently represent hydrogen or lower alkyl; R.sub.a represents hydrogen, lower alkyl, halo, trifluoromethyl or lower alkoxy; and pharmaceutically acceptable salts thereof; their preparation and use as lipoxygenase inhibitors are described.

  该公式的化合物为##STR1##其中R代表氢，低级烷基，芳基，双芳基，C.sub.3-C.sub.7-环烷基，芳基-低级烷基，芳基-低级烯基，芳基-低级炔基，芳氧基-低级烷基，芳硫基-低级烷基；C.sub.3-C.sub.7-环烷基-低级烷基，双芳基-低级烷基，芳基-C.sub.3-C.sub.7-环烷基，芳基-C.sub.3-C.sub.7-环烷基-低级烷基或芳氧基-芳基-低级烷基；芳基代表碳环芳基或杂环芳基；Z代表C.sub.1-C.sub.3-烷基或乙烯基，每个未取代或取代为低级烷基；Y代表SO.sub.2或CO；A代表O、S或直接键；B代表低级烷基；或B代表低级烯基，前提是A代表直接键；X代表氧或硫；R.sub.1代表氢，酰基，低级烷氧羰基，氨基羰基，单或双低级烷基氨基羰基，低级烯基氨基羰基，低级炔基氨基羰基，碳环芳基或杂环芳基-低级烷基氨基羰基，碳环芳基或杂环芳基氨基羰基，C.sub.3-C.sub.7-环烷基氨基羰基或C.sub.3-C.sub.7-环烷基-低级烷基氨基羰基；R.sub.2代表低级烷基，低级烷氧羰基-低级烷基，C.sub.3-C.sub.7-环烷基，碳环芳基或杂环芳基，碳环芳基或杂环芳基-低级烷基，C.sub.3-C.sub.7-环烷基-低级烷基，氨基，单或双低级烷基氨基，低级烯基氨基，低级炔基氨基，碳环芳基或杂环芳基-低级烷基氨基，碳环芳基或杂环芳基氨基，C.sub.3-C.sub.7-环烷基氨基，C.sub.3-C.sub.7-环烷基-低级烷基氨基或低级烷氧羰基-低级烷基氨基；R.sub.3和R.sub.4独立地代表氢或低级烷基；R.sub.a代表氢，低级烷基，卤素，三氟甲基或低级烷氧基；以及其药学上可接受的盐。该化合物的制备及其作为脂氧合酶抑制剂的用途已被描述。